AI Arrhythmia Prediction Patch CardioSense Receives FDA Approval: 72-Hour Advance Warning for Atrial Fibrillation and Ventricular Tachycardia
CardioSense patch uses flexible bioelectronic sensors and edge AI chips to continuously monitor ECG signals and provide 72-hour advance warning of arrhythmia events, with clinically validated accuracy of 96.3%.
An AI Cardiologist Stuck to Your Chest
In February 2029, the US FDA approved CardioSense, an AI arrhythmia prediction patch. Developed by Silicon Valley bioelectronics company NeuroCard, this wearable device can provide 72-hour advance warning of atrial fibrillation and ventricular tachycardia, giving patients a crucial window for intervention.
CardioSense resembles a large adhesive bandage, measuring just 2mm thick and weighing 4.5 grams, applied to the left chest area. Its core consists of an electrode array made from flexible bioelectronic materials and a dedicated edge AI chip. The electrodes continuously record ECG signals at 1,000 samples per second, while the AI chip analyzes signal patterns in real time on the device.
CardioSense's predictive capability comes from a deep learning model trained on 2 million ECG records. The model can identify subtle pattern changes invisible to the human eye in ECG signals — changes that typically appear 48-72 hours before arrhythmia events. In a Phase III clinical trial with 3,000 patients, CardioSense achieved 96.3% advance warning accuracy for atrial fibrillation and 93.8% for ventricular tachycardia.
CardioSense has a 14-day battery life, with data syncing to a smartphone app via Bluetooth. When the system detects high-risk signals, it simultaneously alerts both the patient and their attending physician. The device retails for $299 with a $12 monthly data service fee.
Disclaimer
Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.